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ABSTRACT: Macrophage migration inhibitory factor (MIF) is a homotrimeric multifunctional proinflamma-
tory cytokine that has been implicated in the pathogenesis of several inflammatory and autoimmune diseases.
Current therapeutic strategies for targeting MIF focus on developing inhibitors of its tautomerase activity or
modulating its biological activities using anti-MIF neutralizing antibodies. Herein we report a new class of
isothiocyanate (ITC)-based irreversible inhibitors ofMIF.Modification by benzyl isothiocyanate (BITC) and
related analogues occurred at the N-terminal catalytic proline residue without any effect on the oligomeriza-
tion state of MIF. Different alkyl and arylalkyl ITCs modified MIF with nearly the same efficiency as BITC.
To elucidate the mechanism of action, we performed detailed biochemical, biophysical, and structural studies
to determine the effect of BITC and its analogues on the conformational state, quaternary structure, catalytic
activity, receptor binding, and biological activity ofMIF. Light scattering, analytical ultracentrifugation, and
NMR studies on unmodified and ITC-modified MIF demonstrated that modification of Pro1 alters the
tertiary, but not the secondary or quaternary, structure of the trimer without affecting its thermodynamic
stability. BITC induced drastic effects on the tertiary structure of MIF, in particular residues that cluster
around Pro1 and constitute the tautomerase active site. These changes in tertiary structure and the loss of
catalytic activity translated into a reduction in MIF receptor binding activity, MIF-mediated glucocorticoid
overriding, and MIF-induced Akt phosphorylation. Together, these findings highlight the role of tertiary
structure in modulating the biochemical and biological activities of MIF and present new opportunities for
modulating MIF biological activities in vivo.
Macrophage migration inhibitory factor (MIF)1 is a multi-
functional protein that is now recognized as a major player in
innate immune responses and regulation of the host response to
inflammation and infection.MIF is expressed in a variety of cells
and has been implicated in a wide range of cellular activities,
including transcriptional regulation of inflammatory gene pro-
ducts (1), regulation of glucocorticoid activity (2), cell cycle
control via promotion of cell proliferation and survival through
activation of the ERK1/2 MAPKs (3), inhibition of the p53 and
retinoblastoma/E2F tumor suppressor pathways (4, 5), and
activation of the phosphoinositide 3-kinase (PI3K)/Akt survival
pathway (6). Several lines of evidence support a central role for
MIF in the pathogenesis of inflammatory and autoimmune
diseases, including arthritis (7, 8), glomerulonephritis (9, 10),
diabetes (11, 12), colitis (13), sepsis (14-18), acute respiratory
distress syndrome (19, 20), and cancer (21-23). Therefore,
targeting MIF activity has emerged as a viable therapeutic
approach for treating these inflammatory and autoimmune
diseases.
In addition to its reported biological activities, MIF is
known to catalyze the tautomerization of phenyl pyruvate (or
hydroxyphenyl pyruvate) and D-dopachrome methyl ester
(Figure 1) (24-27). Although the physiological substrates of
MIF remain unknown, and the exact relationship between its
catalytic activity and biological function is still not well under-
stood, targeting MIF tautomerase activity using small-molecule
inhibitors has emerged as a viable strategy for inhibiting MIF
proinflammatory activity and attenuating its biological activity
in vitro and in vivo (28-30). The first example of a small-
molecule MIF inhibitor was NAPQI, which was described by
Senter et al. to form a covalent complex with the MIF catalytic
proline residue (Pro1) (Figure 1), thereby eliminating tautomer-
ase activity. NAPQI-modified MIF failed to override the im-
munosuppressive effect of dexamethasone on LPS-induced TNF
production by monocytes but has not been tested in the clinic
because of its potential toxicity (31). Al-Abed and co-workers
subsequently developed several active site inhibitors based on
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modifications of the scaffold of (S,R)-3-(4-hydroxyphenyl)-4,5-
dihydro-5-isoxazole acetic acid methyl ester (ISO-1) (32, 33).
MIF tautomerase inhibitors, including ISO-1, phenolic hydra-
zone (34), OXIM-11 (29), and COR10014 (30), were shown to
have protective effects in animal models of sepsis and RA.
Inhibition of MIF tautomerase activity by these molecules was
also accompanied by modulation of its biological activities,
including inhibition of (1)MIF glucocorticoid overriding activity
and (2) endotoxin (LPS)-induced TNF production and MIF-
mediated (i) stimulation of ERK1/2 MAP kinase and prolifera-
tion of serum-starved cells (33), (ii) upregulation of arachidonic
acid in macrophages, and (iii) Cox-2 activation.
Herein we report a new class of ITC-based irreversible
inhibitors of MIF. To elucidate their mechanism of action, we
performed detailed biochemical, biophysical, and structural
studies to determine their effect on the conformational state,
quaternary structure, enzymatic activity, receptor binding, and
biological properties of MIF. These studies demonstrate that in
addition to blocking the catalytic activity of MIF, selective
modification of Pro1 alters the tertiary structure of MIF and
results in a significant reduction in the level of MIF-mediated
glucocorticoid overriding and MIF-induced Akt phosphoryla-
tion. These findings and their implication for therapeutic strate-
gies targeting MIF are presented and discussed.
MATERIALS AND METHODS
Chemicals. Benzyl isothiocyanate (BITC), allyl isothiocya-
mate (AITC), ethyl isothiocyanate (EITC), methallyl isothiocya-
nate (MITC), 2-piperidinoethyl isothiocyanate (2PITC), cyclo-
propyl isothiocyanate (CPITC), and phenylethyl isothiocyanate
(PEITC) were purchased from Sigma or Fluka and were of the
highest purity available.
Expression and Purification ofHumanMIF.MIF protein
was expressed by heat shock transformation of the BL21DE3
Escherichia coli strain (Stratagene) with bacterial expression
vector pET11b containing the human MIF gene under control
of the T7 promoter. Four hours postinduction, the cells were
harvested, resuspended in lysis buffer (50 mMTris, 50 mMKCl,
5 mM MgAc, and 0.1% azide), sonicated at a 200 Hz pulse
repetition frequency for 20 min using a VibraCellTM sonicator,
and harvested by centrifugation at 13000g for 25 min. The
clarified cell lysate was filtered, injected onto a MonoQ anion
exchange column (HiPrep 16/10 Q FF, GE Healthcare), and
eluted with a linear NaCl gradient in elution buffer [25 mMTris-
HCl (pH 7.4) and 150 mM NaCl]. The flow-through fractions
containing MIF were pooled and loaded onto a Superdex 75 16/
60 (HiLoad 16/60, Superdex 75, Pharmacia Biotech) gel filtration
column. Fractions corresponding to MIF were pooled together,
dialyzed against PBS, and filtered. The identity and purity of the
protein were confirmed by MALDI-TOF mass spectrometry,
silver staining, and Western blotting using the rabbit anti-MIF
antibody from Zymed (Invitrogen) at a dilution of 1:20000.
When required, the proteins were concentrated using a concen-
trator with a molecular mass cutoff of 5 kDa and stored at 4 C
until theywere used.Uniformly 15N-labeled protein samples were
prepared for NMR experiments by culturing the bacteria in M9
minimal medium containing [15N]ammonium chloride (1 g/L) as
the only nitrogen source. Recombinant MIF used for cellular
studies was subjected to LPS removal as described pre-
viously (35). Briefly, Bacterial cell lysate was injected into an
anion exchange column; the flow-through fractions containing
MIF were applied to C8-Seppak cartridge, and MIF was eluted
with a 60% acetonetrile/water mixture, lyophilized, and renatu-
rated. The LPS content was quantified using a chromogenic
Limulus amoebocyte assay.
Analytical Ultracentrifugation (AUC). Analytical ultra-
centrifugation experiments were performed using purified and
dialyzed MIF samples (10-20 μM) preincubated with BITC for
1 h at an MIF concentration corresponding to 100% inhibition.
FIGURE 1: Trimer formation is required for MIF tautomerase activity. (A) Ribbon diagram showing the MIF homotrimer and the tatuomerase
active site. Eachmonomer is indicated by a different color. The figurewas generated usingVMD, andPDB entry 1GDOhas a resolution of 1.5 A˚.
TheMIF catalytic site complexed with (E)-2-fluoro-p-hydroxycinnamic acid indicates that themolecules interact through the side chains of Pro1,
Lys32, and Asn97 from two neighboring subunits. (B) Mechanism of MIF tautomerase reaction as proposed by Stamps et al. (27).
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Radial UV scans were recorded on a Beckman Optima XL-A
instrument at a wavelength of 277 nm. Sedimentation velocity
experiments were conducted at 20 C using 380-400 μL of pro-
tein solution.Datawere recorded at a rotor speed of 50000 rpm in
continuous mode, with a step size of 0.003 cm. The experimen-
tally determined partial specific volume of 0.765mg/mLwas used
to calculate themolecularmasses ofMIF (36). The sedimentation
velocity profiles were analyzed as a c(s) distribution of the Lamm
equation using SEDFIT. Molar mass distributions c(M) were
obtained by transforming the corresponding c(s) using SEDFIT.
Analytical Size Exclusion Chromatography and Light
Scattering. Size exclusion chromatography experiments were
performed on purified MIF incubated in the presence and
absence of BITC or its analogues using an analytical Superdex
75 10/30 column at room temperature. The column was equili-
brated with 25 mM Tris buffer (pH 7.6), and MIF samples
(12 μM in 1 PBS) in volumes of 0.5 mL were injected onto the
column and eluted at a flow rate of 0.4 mL/min in an Agilent
HPLC system attached to both a UV, refractive index and a
DAWN HELLIOS multiangle light scattering detector (Wyatt
Technology Corp., Santa Barbara, CA). Absolute molecular
masses were determined using ASTRA version 5.3 from Wyatt
Technology.
MALDI-TOF-MS Molecular Mass Measurements for
Examining Possible Protein Modifications. Matrix-assisted
laser desorption ionization time-of-flight mass spectrometry
(MALDI-TOF-MS) was performed to examine any HITS-
induced protein modification. We prepared the matrix solution
by dissolving a 14 mg/mL sinapinic acid (SA) solution in a 0.1%
TFA/ACN mixture (1:1). A thin matrix layer was generated on
the mirror-polished target using a gel loading tip. One microliter
of sample (15 μMMIF incubated with 10 μMHITS for 1 h) was
mixedwith 1 μLof SAmatrix solution, and 0.8 μLof thismixture
was deposited on top of the thin layer and allowed to air-dry. The
samples were analyzed with a 4700 MALDI-TOF/TOF instru-
ment (Applied Biosystems).
Protein Digestion Analysis for Identifying the Modified
Residue.Onemicroliter of theMIF sample previously incubated
for 1 h with 10 μMBITC was diluted in 5 μL of 100 mMBA and
digested overnight with trypsin (Promega). The digestion was
stopped with 1 μL of 10% TFA and the mixture stored at 4 C
until further use. The samples were analyzed by MALDI-TOF-
MS on a 4700 MALDI-TOF/TOF instrument (Applied Bio-
systems) or an Axima CFR plus instrument (Shimadzu) without
further purification. One microliter of sample was mixed with 1
μL of DHB [20 mg/mL in a 1% PA/ACNmixture (1/1)], and 0.8
μL of this mixture was deposited on the target and allowed to air-
dry. MALDI matrices and calibrants were obtained from Sigma/
Fluka (Schnelldorf, Germany). TFA was from Pierce. SA and
2,5-dihydroxybenzoic acid (DHB)were fromFluka. Cytochrome
c and apomyoglobin were from Sigma.
Nuclear Magnetic Resonance (NMR) Spectroscopy.
NMR spectra were recorded at 27 C on a Bruker Avance
600MHzNMR spectrometer using a triple-resonance cryoprobe
equipped with z-axis self-shielded gradient coils. Measurements
were performed using 100-200 μM samples. All samples were
prepared in 20mMNa2HPO4, 0.5mMEDTA, 0.02%NaN3 (pH
7.0), and 10% D2O. Two-dimensional
1H-15N heteronuclear
single-quantum coherence (HSQC) spectra were recorded using
256  1024 complex data points in the F1 and F2 dimensions,
with a relaxation delay of 1.0 s. Sixty-four scans per increment
were recorded for each spectrum. Spectral widths were 2200 and
8950 Hz in the 15N and 1H dimensions, respectively. Specifically,
we recorded two-dimensional 1H-15N HSQC spectra to follow
chemical shift changes upon addition of inhibitory compounds
and to map the interaction surface of MIF for each compound.
For this, a reference spectrum of MIF alone was recorded in the
presence of 1% DMSO. For each titration step of MIF with
inhibitory compounds, a new sample was prepared inwhichMIF
was mixed with the corresponding compound dissolved in
DMSO, with the DMSO concentration maintained at 1%.
Spectra were processed with Topspin (Bruker) and NMR-
Pipe (37). Visualization and manipulation were performed using
the public domain graphics program Sparky 3 (59). Resonance
assignmentswere previously published for the same buffer system
at 30 C (38). The addition of 1% DMSO and a small change in
temperature did not interfere with the transfer of resonance
assignments. Both intensity and chemical shift differences were
analyzed with respect to the reference spectrum. Mean weighted
1H-15N chemical shift differences were calculated according
to the relationship Δδ = ({(Δδ1H)2 þ [(Δδ15N)/5]2}1/2)/2 (39).
Changes were mapped on the crystal structure using PDB entry
1GDO (1.5 A˚ resolution) and PyMOL.
MIF Receptor Binding Assay. Recombinant, soluble hu-
MIF receptor ectodomain (sCD7473-232) was cloned and pur-
ified as described previously (40) and used to coat 96-well plates
by incubation at 4 C overnight. Plates were washed four times
with TTBS (pH 7.4) and blocked with superblock buffer (Pierce)
for 1 h at room temperature. Biotinylated huMIF (Roche Mole-
cular Biochemical) was prepared and added together in triplicate
wells with increasing concentrations of purified huMIF tri-
mer (35), heat-denatured huMIF, or test MIF proteins. Incuba-
tion took place at room temperature for 2 h. After wells had been
washed four times with TTBS (pH 7.4), streptavidin-conjugated
alkaline phosphatase (R&D) was added and incubation contin-
ued for an additional 1 h, and the wells were washed and bound
complexes detected via addition of p-nitrophenyl phosphate
(Sigma). Absorbance was read at 405 nm using a DYNATECH,
MR5000 plate reader, and values were plotted as percent OD405
relative to wells containing biotinylated MIF alone. The plots
shown are representative of at least three assays, and each plotted
point depicts a standard error of the mean of e10%.
Glucocorticoid Overriding Assay. PBMCs from healthy
donors (recruited by the Blood Center, Lausanne, Switzerland)
were purified with a Ficoll-Hypaque density gradient (GE
Healthcare). To obtainmacrophages, adherent PBMCs (106 cells
per well in 48-well plates) were cultured for 6 days in RPMI 1640
with Glutamax. Media were supplemented with 10% heat-
inactivated FCS (Seromed) and antibiotics. MIF was incubated
with the inhibitors for 15 min at room temperature. Primary
macrophages were preincubated for 1 h with 100 nMdexametha-
sone, dexamethasone with MIF (100 ng/mL), or dexamethasone
with MIF and BITC (10 μM) before the addition of 100 ng/mL
Salmonella Minnesota Ultra Pure LPS (List Biologicals Labo-
ratories). TNF concentrations in cell culture supernatants col-
lected after 4 h were measured with a bioassay. Statistical ana-
lyses were performed using one-way ANOVA followed by
Scheffe’s test for BITC treatment from four independent experi-
ments. A p< 0.05 significance was required for rejection of the
null hypothesis.
Phospho Akt Activation by MIF. Confluent HeLa cells
were incubated for 2 hwith recombinant humanMIF (50 ng/mL)
in the presence of BITC, LY294002 (10 and 1 μM), or DMSO.
Phosphorylation of Akt (Ser473) was assessed using an Alpha
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screen SureFire phosphokinase kit, an immunosandwich assay
based on alpha screen technology in two incubation steps,
according to the manufacturer’s protocol. First, cell lysate
was incubated for 2 h with an anti-Akt antibody captured on
protein A-conjugated acceptor beads. Then, the biotinylated
anti-pAkt antibody was added with streptavidin-coated Alpha
donor beads. The two beads were brought into the proximity of
each other only in the presence of phosphorylated Akt. Upon
illumination at 680 nm, the Alpha donor bead photosensitizer
converts the ambient oxygen to an excited form, which will
enable the excitation of the Alpha acceptor beads. Data are
reported as Alpha screen counts. Statistical analyses were per-
formed using one-way ANOVA followed by Scheffe’s test for
compound treatment from three independent experiments. A p
< 0.05 significance was required for rejection of the null
hypothesis.
RESULTS
Benzyl Isothiocyanate (BITC) Inhibits MIF Tautomer-
ase Activity. During our screening for inhibitors of MIF
tautomerase activity, we observed that BITC demonstrated
100% inhibition of the tautomerase activity of both human
and murine MIF at concentrations of 10 μM. We hypothesized
that this inhibitory activity is due to the reactivity of the
isothiocyanate group in BITC. To test this hypothesis, we
evaluated the inhibitory effect of several ITCs at concentrations
ranging from 0 to 100 μM and obtained IC50 values 0.79, 3.69,
11.10, 1.43, and 3.09 μM for BITC, AITC, EITC, MITC, and
2PITC, respectively (Figure 2).
BITC Mode of Action. Inhibition of MIF’s tautomerase
activity can occur via at least five different mechanisms: (1)
binding to the active site, (2) allosteric inhibition, (3) covalent
modification of active site residues, (4) disruption of the active
site through compound-induced dissociation of the active trimer,
and (5) stabilization of the MIF monomer and prevention of its
reassociation to form the active trimer. To elucidate the mechan-
ism of action of BITC, we performed detailed biochemical,
biophysical, and structural studies to determine the effect of
BITC and its analogues on the conformational state, quaternary
structure, catalytic activity, receptor binding, and biological
activity of MIF.
BITC Inhibition of MIF Tautomerase Activity Is Medi-
ated by Selective Modification of the N-Terminal Proline.
BITC contains the isothiocyanate reactive group which can
readily interact with O-, S-, or N-based nucleophiles. As a result,
BITC may react with cysteine residues (41, 42) or with the
N-terminus of the protein, as in the case of phenyl isothiocyanate
(PITC, Ph-NdCdS) used in protein sequencing using Edman
degradation. This raised the possibility that BITC inhibition of
MIF tautomerase activity might occur through covalent mod-
ification ofMIF. To test this, MIF (15 μM) in 50mMTris buffer
(pH 7.4) was incubated with BITC (10 μM) for 60 min and the
formation of a BITC-MIF adduct was monitored by MALDI-
TOF-MS. Under these conditions, a shift in the monomeric
molecular mass ofMIF by 148.33 Da from 12345.16 to 12493.50
Da was observed, which corresponds to the addition of one
molecule of BITC. At concentrations of >10 μM, we observed
complete conversion to the singly modified form of MIF,
consistent with a single-site modification by BITC (Figure 3A
and Figure S1 of the Supporting Information).
To identify the site of covalent modification, we subjected the
BITC-modified MIF to proteolytic digestion by trypsin and
peptide mapping by mass spectrometry. Tryptic digestion of
BITC-modified MIF (Figure 3A) revealed a fragment peptide
with anm/z ratio of 1436.70, which corresponds to the N-terminal
fragment (PMFIVTNTNVPR,m/z 1287.61) with onemolecule of
BITC (Figure 3B). This fragment is devoid of any nucleophilic
residue (lysines and cysteines) that may react with ITCs, except
for the N-terminal proline. MS/MS analysis of this peptide frag-
ment demonstrated that BITC modification takes place at the
N-terminal proline residue. Six additional ITC analogues, AITC,
EITC, MITC, 2PITC, CPITC, and PEITC, were also tested, and
all were shown to modify MIF at the N-terminal Pro residue
(Figure 3C).
BITC Modification Is Specific to MIF. BITC shares
structural similarities with PITC, which is used in N-terminal
polypeptide sequencing, suggesting that its modification of MIF
might not be specific. To assess this possibility, different pro-
teins were incubated with BITC and characterized by MALDI-
TOF. BITC was incubated with ubiquitin, lysozyme, or
R-synuclein at equimolar concentrations either for 1 h or over-
night at room temperature. No modification was detected for
either incubation time byMS, suggesting that the reactivity with
N-terminal proline is specific and likely due to its altered pKa
and increased nucleophilicity (Figure S2 of the Supporting
Information).
BITC Modifies Only Catalytically Active Forms of
MIF. Recent studies from our laboratory demonstrated that
disrupting the conformation of the C-terminus via truncation or
insertion of secondary structure-disrupting elements (proline
residues) within the C-terminal region (residues 104-115) abol-
ished the protein’s activity without altering its oligomerization
state. With these constructs at our disposal, we were interested
in further probing the specificity of BITC-induced modifica-
tion of MIF by determining whether BITC selectively modifies
enzymatically active MIF. Six trimeric MIF variants [three
enzymatically active (Wt, R73A, and N110C) and three inac-
tive (R73AΔ5, R73AΔ10, and P107)] were tested via incuba-
tion with BITC. As expected, MALDI-TOF analysis revealed
total modification of the enzymatically active forms ofMIF (Wt,
N110C, and R73A), whereas no modification was observed
FIGURE 2: Several isothiocyanate-based compounds inhibit MIF
tautomerase activity in a concentration-dependent manner. IC50
concentration response curve (mean ( standard deviation; n = 8)
obtained by monitoring the initial velocity of tautomerization of the
HPP keto form to the HPP enol form by MIF. MIF (100 nM) was
preincubated with different concentrations of ITC analogues BITC,
AITC, EITC,MITC, and 2PITC for 5 min, followed by the addition
of 2 mM hydroxyphenyl puryvate, and then the absorbance was
monitored at 300nm for 5min.The initial velocitywas calculated and
normalized to the percentage of activity.
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for inactive MIF proteins (R73AΔ5, R73AΔ10, and P107),
suggesting that BITC modifies only catalytically active trimeric
forms of MIF (Figure 4).
Modification by BITC and Other ITCs Does Not Alter
the Oligomerization State ofMIF. To determine whether any
of the ITCs function by disrupting theMIF trimer, we compared
the quaternary structure distribution of MIF in the presence or
absence of BITC (6 μM) by sedimentation velocity analytical
ultracentrifugation, size exclusion chromatography (SEC), and
light scattering (Figures 5 and 6). MIF preincubated either with
DMSOas a control or with BITC sedimented predominantly as a
single species with a sedimentation coefficient and molecular
mass corresponding to those of the trimer (Figure 5). Previous
studies fromour laboratory demonstrated thatMIF elutes as two
peaks in the SEC that correspond to two different conformations
of the trimers (43). The two different conformational states of the
trimer differ mainly in their tertiary structure. To determine if
Pro1 modification by the ITCs affects the distribution of the
different trimers, we compared the elution profiles andmolecular
mass distribution of MIF before and after modification by ITCs
by online SEC coupled to a multiangle light scattering detector.
Figure 6 demonstrates thatmodification of Pro1 by all active ITC
MIF inhibitors resulted in a shift in the elution profile ofMIF. In
each case, the covalently ITC-modified MIF elutes as a single
peak at 28 min, whereas the unmodified MIF elutes as a mixture
of two overlapping peaks (31 and 33 min). The light scattering
results demonstrate that this shift in the SEC profile does not
correspond to a change in oligomerization state and is likely to be
due to differences in tertiary structure between the modified and
the unmodified trimer forms of MIF. In each case, the ITC-
modified MIF exhibited a molecular mass corresponding to the
trimer. These findings provide strong evidence in support of our
FIGURE 3: BITC and other isothiocyanate-basedMIF inhibitors covalentlymodify the catalytic N-terminal proline residue (Pro1). (A)MIFwas
incubated in the presence or absence of BITC or one of its analogues (10 μM) for 30min, and the samples were then prepared using sinapinic acid
as a matrix and analyzed byMALDI-TOF/TOF in linear positive ion mode. (B) MIF was incubated with 10 μMBITC for 60 min and digested
with trypsin 1/50ONat 37 Cand pH8.After being desalted, the samples were analyzed byMS. (C) Schematic depiction of the chemical reaction
leading to the formation of a covalent adducts between Pro1 of MIF and BITC.
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hypothesis that theMIF trimer exists in different conformational
states.
Elucidating the Structural Basis for the Inhibition of
MIF Enzymatic Activity Using NMR. To further elucidate
the structural basis for the inhibition of MIF enzymatic activity,
NMR titrations were performed with BITC. An equimolar
mixture of MIF with BITC results in severe resonance broad-
ening throughout the whole sequence, indicative of conforma-
tional exchange. However, more drastic effects are seen for
residues 3, 4, 32, 35-39, 49, 50, 58-67, 79, 84-89, 95-97, 103,
107-109, and 112-114 (Figure 7A,B). The majority of these
residues cluster around P1 and are components of the active site
(Figure 7C). Similar effects had been previously observed in an
NMR titration of MIF with HPP (44). Additionally, Y95 and
N97 are components of the active site. The subunit interface is
not as hydrophobic as the interior of the monomer; however,
there is a hydrophobic patch on the surface. Residues Y36, Y95,
W108, and F113 are part of this patch.
Inhibitors of MIF Tautomerase Activity Interfere with
Binding of MIF to Its Receptor, CD74. A major cellular
action of MIF is to inhibit activation-induced apoptosis by
inducing sustained MAP kinase (ERK1/2) activation (3, 23).
MIF-dependent ERK1/2 phosphorylation proceeds by engage-
ment of a two-component receptor complex that comprises the
binding protein, CD74, and the signal initiating component
CD44 (40, 45). Because the tautomerase site has been implicated
in receptor binding (31, 46), we tested the ability of selected
tautomerase inhibitors to inhibit the interaction of MIF with the
soluble CD74 ectodomain (CD7473-232 or sCD74) using an
ELISA-based MIF “capture” assay (47). We tested the potential
inhibitory action of the N-terminal catalytic site modifier, BITC,
as well as the isothiocyante-based congeners, AITC, EITC,
MITC, and 2PITC (Figure 8). With the possible exception of
2PITC, these compounds exhibited no significant dose-depen-
dent effect at the concentrations tested, and inhibition plateaued
at approximately 30-35%. Taken together, these data suggest
FIGURE 4: Only enzymatically active forms of theMIF trimer undergo covalentmodification byBITC and its active analogues. Six trimericMIF
variants [three enzymatically active (Wt, R73A, and N110C) and three inactive (R73AΔ5, R73AΔ10, and P107)] were tested via incubation with
10 μM BITC for 60 min, and the samples were then analyzed by MALDI-TOF/TOF.
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that that these compounds impart sufficient structural alterations
on MIF to influence its interaction with CD74.
BITC Inhibits MIF-Mediated Glucocorticoid Overrid-
ing Activity and Enhancement of Akt Phosphorylation.
Among the important in vivo immunoregulatory functions of
MIF is its ability to counter-regulate the immunosuppressive
effect of glucocorticoids on proinflammatory cytokine produc-
tion (2). To examine whether BITC interferes with the immunor-
egulatory function ofMIF, humanmacrophages were pretreated
with dexamethasone (100 nM)with orwithout recombinantMIF
(100 ng/mL) and BITC (10 μM) prior to stimulation with LPS.
Whereas dexamethasone inhibited TNF production by LPS-
stimulated monocytes, preincubation with MIF overcame dex-
amethasone inhibition of TNF production (Figure 9A). Inter-
estingly, incubation of MIF with BITC before addition to
dexamethasone abrogated MIF-mediated dexamethasone over-
riding. It is noteworthy that BITC decreased TNF production
even more potently than dexamethasone, suggesting that BITC
has anti-inflammatory activity that is independent of its effect on
MIF structure and tautomerase activity (Figure 9A). Similar
results were obtained using the RAW 264.7 mouse macrophage
cell line. To rule out the possibility that the observed effects were
due to BITC toxicity, we verified that BITC did not alter
macrophage viability under the culture conditions used to induce
TNF production (data not shown).
Previous studies have shown that MIF promotes cell survival
through activation of the PI3K/Akt pathway(48). The addition
of recombinantMIF enhanced Akt phosphorylation via PI3K in
NIH3T3 and HeLa cells (48). To determine whether BITC
antagonized MIF-mediated Akt phosphorylation, we quantified
the level of phosphorylated Akt in HeLa cells cultured for 2 h
withMIF (50 ng/mL) preincubated with BITC or not. As shown
in Figure 9B, MIF increased 1.5-fold the level of phosphorylated
Akt in HeLa cells. BITC (1 and 10 μM) inhibited MIF-induced
Akt phosphorylation. The effect of BITCwas specific forMIF, as
BITC alone did not modify baseline Akt phosphorylation in
HeLa cells. PI3K selective inhibitor LY294002, a known potent
inhibitor of Akt, was used as a control. Overall, these data
indicated that BITC was a powerful inhibitor of MIF biological
activity.
DISCUSSION
Irreversible inhibition of MIF enzymatic activity via covalent
modification of the N-terminal catalytic proline (Pro1) has been
described for severalMIF inhibitors, including 2-oxo-4-phenyl-3-
butynoate (2-OB) (49), acetaminophen metabolites and related
analogues (31), and 4-iodo-6-phenylpyrimidine (4IPP) (50). 2-OB
also was shown to modify the catalytic N-terminal proline of
4-oxalocrotonate tautomerase (4-OT), a member of the tauto-
merase superfamily that shares structural and functional simila-
rities with MIF. Herein we also show that irreversible
modification of MIF by BITC abolished MIF tautomerase
activity, reduced the level of binding of MIF to the CD74
receptor, and resulted in a significant reduction in the level of
MIF-induced Akt phosphorylation. Different alkyl and arylalkyl
ITCs were shown to exhibit similar effects, suggesting that the
inhibitory effect of ITCs is mediated by the reactive isothiocya-
nate group. Although ITCs are known to react with lysine and
cysteine residues, MIF contains three cysteines and three lysine
residues per monomer; using proteolytic digestion and peptide
mapping, we did not observe any modifications at these residues
and could identify modifications only at Pro1. These results can
be explained by the fact that the pKa of Pro1 is reduced by 5 pH
units (27), making it the most nucleophilic residue at physiolo-
gical pH.
Isothiocyanates (ITCs) are abundant in cruciferous vegetables
(e.g., broccoli, kale, brussel sprouts, cabbage, mustard, garden
cress, cauliflower, and water cress). Epidemiological studies have
shown that consumption of high levels of ITCs may protect
against lung, colon, and other types of inflammation-related
carcinogenesis, including skin cancer (51). ITCs, including BITC,
have also been shown to inhibit cell proliferation, induce cell cycle
arrest and apoptosis, and exhibit anticancer properties in differ-
ent animal and cellular models of cancer (51-55).
To elucidate the molecular and structural basis underlying the
inhibitory effect of BITC, we performed detailed biochemical,
biophysical, and structural studies to determine the effect of Pro1
modification by BITC and other ITCs on the conformational
state, quaternary structure, enzymatic activity, receptor binding,
and biological properties of MIF. Together, our results demon-
strate that covalent modification of Pro1 by BITC and other
ITCs results in significant changes in the tertiary, but not the
quaternary, structure of theMIF trimer. NMR studies show that
BITC induces drastic effects on the tertiary structure of MIF, in
particular, residues 3, 4, 32, 35-39, 49, 50, 58-67, 79, 84-89,
95-97, 103, 107-109, and 112-114 that cluster around Pro1 and
constitute the tautomerase active site (Figure 7C), which explains
its diminished tautomerase activity. BITC-modified MIF exists
predominantly as a single species corresponding to the trimer (by
SEC, AUC, and light scattering) and eluted via SEC as a single
peak at 28 min, whereas the unmodified protein elutes as a
mixture of two overlapping peaks at 31 and 33 min, both
corresponding to the MIF trimer. These changes in tertiary
structure translated into a reduction in MIF biological activity,
i.e., binding to CD74 MIF receptor, MIF overriding of gluco-
corticoid-mediated inhibition of TNF production by macro-
phages, and MIF-induced Akt phosphorylation in HeLa cells.
Conformational Changes, Rather Than theLoss ofCata-
lytic Activity,May Explain the Biological Consequences of
Modifying the Catalytic Activity of MIF. Although the
relationship between the enzymatic and biological activity of
MIF remains unclear (32, 56), several small-molecule inhibitors
FIGURE 5: Covalentmodification ofMIFbyBITCdoes not affect its
oligomerization state. Sedimentation velocity profiles of MIF in the
presence or absence of BITC.MIF (10 μM) in PBSwas preincubated
with 6 μM BITC for 1 h at room temperature. Sedimentation
coefficient distributions were obtained by analysis of the sedimenta-
tion profiles using the C(s) distribution as a variant of Lamm
equation solutions. Calculations were performed using SEDFIT
(www.sedfit.com) .
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of MIF tautomerase activity have been shown to protect against
the proinflammatory effects of MIF in vitro and in vivo (28, 33,
34). These findings have been used to support the hypothesis that
the tautomerase activity ofMIF plays a direct role in modulating
its biological activities in vivo. However, several lines of evidence
argue against this hypothesis and suggest that inhibition of MIF
tautomerase activity is not sufficient to abolish its proinflamma-
tory function. (1) Several catalytically inactive mutants of MIF
FIGURE 6: ITC modification of MIF stabilizes a trimeric form that is distinct from those adopted by the wild-type protein. MIF alone (;) and
MIF incubated (---) with 10 μMMITC (A), 2PITC (B), AITC (C), BITC (D), and EITC (E) were injected into an analytical Superdex 75
column and analyzed by light scattering upon elution. The individual data points show the molecular masses at each point in the chromatogram.
Measurements were performed at a protein concentration of 10 μM, in 1 PBS at pH 7.4.
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retain their proinflammatory activity in vitro. (2) C-Terminal
deletion of 5-10 C-terminal amino acids (residues 104-114)
abolishes the catalytic activity of MIF without affecting its
binding to the receptor CD74 (43) which plays a key role in
modulating the signal transduction activity of MIF. (3) The
catalytically inactive P1G mutant retains its binding to the MIF
cell surface receptor (CD74) and intracellular binding protein
JAB1/CSN5, albeit with some loss of affinity (56). (4) Studies on
the P1G-MIF knockin mice (mif P1G/P1G) demonstrate that the
tautomerase activity of MIF is not essential for its growth
regulatory properties (56).
These two hypotheses can be reconciled by the possibility that
small-molecule interactions or covalentmodification of the active
site induces conformational or quaternary structural changes
that modify protein-protein interactions that mediate MIF
biochemical and biological properties. Given that MIF is tri-
meric, it is reasonable to consider that changes in the oligomer-
ization state of the protein may underlie its multifunctional
properties. To date, however, all the X-ray structure studies
and in solution characterization of MIF using different techni-
ques reveal that MIF exists as a stable trimer, and no evidence of
a stable dimeric or monomeric MIF has been reported. It is
noteworthy that the concentration of native MIF is in the range
of 4-16 nM. Therefore, we cannot rule out the possibility that
there is a substantial amount of monomeric MIF under physio-
logical conditions. Although our data suggest that the monomer
is unstable and has a strong propensity to aggregate, it is possible
that under physiological conditions the monomer is stabilized
by its interactions with small molecules, peptides, or proteins in
the cell.
We propose that the conformational heterogeneity, rather
than quaternary structure, of MIF plays a role in modulating its
protein-protein interaction and biochemical and biological
activity and underlies its multifunctionality. This hypothesis is
consistent with recent studies from our group demonstrating that
the MIF trimer in solution exists in two different conforma-
tional states that differ primarily at the level of tertiary structure
(F. El-Turk et al., unpublished data). These solution studies
are supported by recent X-ray crystallography studies of the
two Leishmania major orthologues of MIF (LmjMIF1 and
LmjMIF2) (57). Both LmjMIF and LmjMIF2 crystallize in a
trimeric form similar to that of mammalian MIF, but only
LmjMIF1 is enzymatically active. Comparison of the X-ray
structure revealed subtle structural differences between the two
isoforms, mainly in the N-terminal region comprising residues
30-37. Interestingly, C-terminal mutations that abolish the
FIGURE 7: CovalentmodificationofPro1byBITC induces drastic changes in the tautomerase active site ofMIF. (A) Superimposed contourplots
of the 1H-15NHSQCspectra of 15N-labeledMIF in the free state (black) and for anequimolarmixture ofMIFandBITC(red)measuredat 27 C.
AdditionofBITC toMIF results in severe resonance broadening. (B)Changes in individual cross-peak intensities ofMIF (100μM)uponaddition
of 50 (gray) and 100μM(red)BITC. (C)Residues affecteduponadditionofBITCmapped into the crystal structure of theMIFhomotrimer (PDB
entry 1GDO). Residues that are affected cluster around P1 (red). The two views are related to each other by an angle of 90.
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catalytic activity of MIF favor the formation of a trimeric
conformation that is distinct from those populated by the wild-
type protein (43). Studies by Bucala and colleagues demonstrated
that covalentmodification ormutation of Pro1 induces structural
changes at the N-terminus that alter its recognition by mono-
clonal antibodies and result in a significant reduction inMIF cell
surface binding activity (31). These findings demonstrate that
MIF is capable of adopting different trimeric states that seem to
differ primarily at the levels of tertiary structure, catalytic
activity, and receptor binding activity.
Previously, we showed that C-terminal deletion mutants (ΔC5
huMIF1-109 and ΔC10 huMIF1-104) and a mutant in which the
secondary structure of the C-terminal region comprising residues
104-114 has been disrupted by the insertion of proline at
position 107 (P107 huMIF) are catalytically inactive and elute
as a single trimeric peak which elutes earlier than the unmodified
protein. Unlike the BITC-modified MIF, all the C-terminal
deletion mutants (ΔC5 huMIF1-109 and ΔC10 huMIF1-104)
exhibited virtually identical binding to CD74. These findings
suggest that C-terminal residues 105-114 may not be directly
involved in the binding to CD74 and further support a direct
relationship between the N-terminal region in modulating the
structural properties and protein-protein interactions mediating
the biological activity of MIF. Together, our results combined
with the lack of data supporting the existence of a stable
monomeric MIF highlight the role of tertiary structure rather
than quaternary structure in modulating the biochemical and
biological activities of MIF. At this stage, we cannot rule out a
biological role for monomeric MIF in vivo and the possibility
that changes in the oligomerization state may also constitute a
molecular switch for modulating different functions of MIF.
Our observation that BITC and its analogues modify only
enzymatically active conformations of MIF and induce further
conformational changes that alter MIF receptor binding proper-
ties highlights the potential of new strategies for monitoring and/
or modulating MIF’s activity in health and disease. Conforma-
tional changes that alter the active site or pKa of the catalytic
proline residue appear to be sufficient for abolishing MIF
reactivity toward BITC and other ITCs. These results suggest
that altering the catalytic site via selective modification of the
FIGURE 8: ITC-based inhibitors ofMIF tautomerase activity interfere with binding ofMIF to its receptor, CD74. Dose-dependent inhibition by
isothiocyante derivatives (A) BITC, (B)AITC, (C) EITC, (D)MITC, and (E) 2PITC. Test compoundswere preincubatedwith 2 ng/μLof 0.2 μM
biotinylatedMIF equal to 0.16 μMfor 2 h at room temperature in the dark prior to addition to 96-well plates precoatedwith recombinant human
sCD74. Data points are the means of duplicate determinations of bound MIF.
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N-terminal proline residue may present new opportunities for
modulating MIF biological activities in vivo. More recently,
Merk et al. also demonstrated that covalent modification of Pro1
by 4-iodo-6-phenylpyrimidine (4-IPP) blocks MIF secretion by
influencing its interaction with p115, a Golgi complex-associated
protein recently identified as a key partner of MIF and mod-
ulator of its secretion (58). A change in the native conformation
of MIF was proposed as a mechanism underlying the effect of
4-IPP on MIF-p115 interaction, although the nature of this
change was not investigated. These findings are consistent with
our results and demonstrate the possibility of regulating MIF’s
protein-protein interactions and activity by modulating its
catalytic activity and suggest different roles for the catalytic
domain and tautomerase activity.
CONCLUSION
We have shown that BITC and other ITCs are effective
inhibitors of MIF tautomerase activity. Although this inhibitory
effect of ITCs is mediated by their covalent modification of the
catalytic N-terminal proline residue, their effect on MIF’s
receptor binding and proinflammatory activity is in part
mediated by changes in the tertiary structure of MIF as a result
of modification of the N-terminus and/or catalytic site. The
design of novel active site-directed irreversible inhibitors based
on structural complementarily with the catalytic active site and
incorporation of reactive groups should yield novel mechanism-
based inhibitors of MIF biological activities. Furthermore, the
specificity and selectivity of BITC reactivity with Pro1, as a
consequence of its low pKa, also open new opportunities for
specific labeling of MIF and monitoring of its activity in vivo.
For example, MIF reactivity with ITCs could be used as an
indirect method to quantify the ratio of active to inactive MIF
trimers in biological samples, which might provide a better
correlation with disease progression and severity than total
MIF levels.
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